Drug

Dronabinol

Established medicine

ClassCannabinoid CB1 receptor agonistResearchOngoing clinical research

Also known as (-)-delta9-trans-Tetrahydrocannabinol, .DELTA.1-THC, 1-trans-delta-9-Tetrahydrocannabinol, Delta-9-tetrahydrocannabinol+13 more

(-)-delta9-trans-Tetrahydrocannabinol, .DELTA.1-THC, 1-trans-delta-9-Tetrahydrocannabinol, Delta-9-tetrahydrocannabinol, Marinol, Syndros, THC, Tetrahydrocannabinol, delta 9-tetrahydrocannabinol, delta(1)-tetrahydrocannabinol, delta(9)-THC, delta-9-THC, delta9-tetrahydrocannabinol, tetrahydrocannabinol (THC), 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol, Dronabinolum, Synthetic delta-9-Tetrahydrocannabinol.

RxNorm10402 ChEMBLCHEMBL465 ATCA04AD10UNII7J8897W37S

Research papers

Active clinical trials

Cannabinoid receptor 1

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Single-site, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Dronabinol for the Treatment of Agitation in Outpatient With Dementia

Clinical trial2026-11-01Withdrawn · ClinicalTrials.gov

Sex Differences in Neurobehavioral Response to Acute THC in Adults With Cannabis Use Disorder

Clinical trial2026-10-06Status changed to Terminated · ClinicalTrials.gov

Investigation of the Effects of Cannabis on the Immune-genome in People With HIV

Clinical trial2026-10-01Primary completion · ClinicalTrials.gov

BONG: Reducing Severe Breathlessness With Dronabinol in the Severe and Very Severe Chronic Obstructive Pulmonary Disease Patient Group - A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Clinical trial2026-09-25Status changed to Active, not recruiting · ClinicalTrials.gov

Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial

Clinical trial2026-09-25Results expected Q4 2027 · ClinicalTrials.gov

The Differential Effects of THC vs. CBD on Cognition in Persons With MS

Clinical trial2026-09-15Results expected Q3 2027 · ClinicalTrials.gov

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Clinical trial2026-09-04Results expected Q1 2027 · ClinicalTrials.gov

High Potency Cannabis: Acute and Protracted Effects

Clinical trial2026-09-04Results expected Q3 2027 · ClinicalTrials.gov

Presynaptic nanoscale components of retrograde synaptic signaling.

Research2024-05-29Science advances

Cannabis effects on driving skills.

Research2012-12-07Clinical chemistry

Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

Research2012-01-30Neurogastroenterology and motility

Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

Research2011-07-29Gastroenterology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Dronabinol

Aliases & brands

(-)-delta9-trans-Tetrahydrocannabinol.DELTA.1-THC1-trans-delta-9-TetrahydrocannabinolDelta-9-tetrahydrocannabinolMarinolSyndrosTHCTetrahydrocannabinoldelta 9-tetrahydrocannabinoldelta(1)-tetrahydrocannabinoldelta(9)-THCdelta-9-THCdelta9-tetrahydrocannabinoltetrahydrocannabinol (THC)3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-olDronabinolumSynthetic delta-9-Tetrahydrocannabinol

RxNorm CUI

10402

ChEMBL ID

CHEMBL465

ATC codes

A04AD10

UNII

7J8897W37S

Primary mechanism

Cannabinoid CB1 receptor agonist